Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exatecan SCHEMBL7255477 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL29351332 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL31615015 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL29601765 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL23471938 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL2512959 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL25349032 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7249645 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7163616 | 0.99 | TOP1 (0.59) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL6047672 | 0.99 | TOP1 (0.59) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11147 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144890-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY | MyricX Pharma Limited (GB) | 2026-05-28 | — | — | US | claimed |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| EP-4748396-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-NECTIN4 ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY AND USE THEREOF | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. (CN) | 2026-05-27 | — | — | EP | claimed |
| CN-116209679-B | Antibody-drug conjugates containing anti-mesothelin antibodies and uses thereof | BIOTECHNOLOGY DEVELOPMENT CENTER (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075734-A | Conjugates comprising tetrapeptides, methods of making, intermediates and uses thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4743124-A1 | DE-N-ACETYLATED POLYSIALIC ACID (DPSA) BINDING AGENT, CONJUGATES, AND METHOD OF USING SAME | Saccharo, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | claimed |
| US-20060135546-A1 | Methods for the purification of 20(S)- camptothecin | CYMBIO PHARMA PVT. LTD. (IN) | 2006-06-22 | — | — | US | claimed |
| WO-2006002119-A2 | KINASE INHIBITORS FOR TREATING CANCERS | GPC BIOTECH, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| WO-2005113018-A2 | CANCER TREATMENT USING VIRUSES AND CAMPTOTHECINS | WELLSTAT BIOLOGICS CORPORATION (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| WO-2005077385-A2 | METHODS FOR TREATING RESISTANT OR REFRACTORY TUMORS | GPC BIOTECH AG (DE) | 2005-08-25 | — | — | WO | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0781781-B1 | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 2001-10-10 | — | — | EP | claimed |